Tetralogy of Fallot patients with pulmonary atresia (TOF/PA) present a pulmonary blood supply directly from aortic collateral arteries. Major aorto-pulmonary collateral arteries (MAPCAs) present substantial clinical and surgical management challenges. Surgical operations to reestablish and promote further development of a pulmonary arterial connection preferentially utilize MAPCAs for reconstruction of central pulmonary arteries. However, the propensity of some MAPCAs to develop stenosis rather than growth may impair the response to reconstructions. Methods: Probe sets prepared from MAPCAs, PA, and aorta mRNA were used to interrogate human genome microarrays. We compared expression differences between pairs of the three vessels to determine whether MAPCAs display distinct expression patterns. results: Functional clustering analysis identified differences in gene expression, which were further analyzed by gene ontology classification. A subset of highly regulated genes was validated using quantitative PCR. Expression differences among vessel types were observed for multiple gene classes. Of note, we observed that MAPCAs differentially express several genes at much higher levels than either PA or aorta. conclusion: MAPCAs differ from PA or aorta by significantly altered levels in gene expression, suggesting a transcriptional basis for their physiology that will guide a further understanding of the pathobiology of MAPCAs and TOF.
M
ajor aorto-pulmonary collateral arteries (MAPCAs) are congenital systemic-to-pulmonary collateral arteries that supply the lung segments of patients with an abnormal pulmonary arterial tree, forming a unique but pathological bridge between the great vessels of the heart. MAPCAs are commonly present in tetralogy of Fallot (TOF) patients having both pulmonary atresia and ventricular septal defect (PA-VSD) (1, 2) . Although their origin is controversial (3, 4) , evidence supports the concept that MAPCAs are the remnants of intersegmental arteries supplying the lung buds in early fetal development, before the intraparenchymal arteries reach the central pulmonary arteries. It is thought that the intersegmental arteries normally regress when the central pulmonary to intraparenchymal artery connection is established. Because of the absence of the normal right ventricle to lung vasculature connection (i.e., presence of PA), the intersegmental arteries apparently continue in confluence with the intrapulmonary vasculature and persist beyond birth (5) as MAPCAs. The pattern of MAPCAs growth is observed to change after birth; their caliber tends not to increase over time as expected. Importantly, within the first few neonatal months they often become irregularly shaped, thickened, kinked, and stenotic, resulting in hypoperfused lung segments. As a consequence of the lack of enlargement of these collaterals, stenoses are usually present at the site of confluence with the pulmonary artery, somewhere between the aorta and the lung, or before their entrance into the parenchyma (6) . These structural modifications may be triggered or accelerated by the postnatal decline in pulmonary vascular resistance, and subsequent increased blood flow velocity and shear stress. Myointimal hyperplasia is more likely to develop in the collaterals with extended exposure to systemic pressure and flow, leading to occlusion of the vessels and loss of lung segments if no other supply is available (7) . Nonstenotic collaterals, on the other hand, supply the pulmonary vasculature under systemic pressure, which ultimately results in obstructive pulmonary vascular disease, loss of lung segments, and pulmonary hypertension (2, (7) (8) (9) .
Patients with VSD and MAPCAs present a total mixing lesion, which results in greater cardiac work due to volume overload, yet reduced systemic oxygen saturation, a condition that promotes a number of pathophysiologic consequences, including ventricular failure. Complex surgical operations are performed to reestablish the pulmonary flow connection, utilizing MAPCAs as raw material for reconstruction of the pulmonary arterial system. Currently, a unifocalization operation is a more-accepted management strategy for these patients. It consists of creating a one-compartment pulmonary arterial system, recruiting as many lung segments as possible by connecting the true pulmonary arteries and the MAPCAs system (10) . The ultimate goal is to reestablish forward flow under pulmonary pressures to further the development of pulmonic arborization (7, 8, 11, 12) . Before this approach, it was estimated that 65% of patients with PA-VSD and MAPCAs would survive to 1 y of age and 50% to 2 y, regardless of surgical intervention (13) . Poor technical reconstruction, including failure to address existing degenerated segments, and late timing are known reasons for a poor outcome after unifocalization (14) . While collaterals left in their original site develop stenosis and obstructions, they tend to grow when unifocalized.
To date, no genome-wide expression profiles (transcriptomes) of vessel tissues from TOF patients have been reported. To better understand the pathophysiology of MAPCAs, we are investigating biologic differences between MAPCAs and their connecting vessels: aorta (AO) and pulmonary artery (PA). Here, we report a comparative analysis of gene expression in MAPCAs and their contiguous vascular connection, the pulmonary artery and aorta vessels. The analysis reveals multiple differences between MAPCAs and the great vessels of the heart.
RESULTS

Comparison of Gene Expression Profiles
We identified 193 differentially regulated genes in MAPCAs (fold > 2.0, P < 0.05, t-test, followed by Benjamini and Hochberg FDR correction) compared with the PA group, and 405 genes in the PA vs. aorta group comparison. However, the largest number of differentially regulated transcripts was observed in the MAPCAs vs. aorta group comparison, which had a total of 466 altered transcripts. The identities of the up-and downregulated genes and their fold-change cutoff are listed in Figure 1a . A comparison of the number of genes differentially regulated in the three vessel groups as well as genes common to the vessel types for two-and fourfold change thresholds are illustrated in Venn diagrams (Figure 1b,c) . Only 20 genes were differentially expressed in common in all three groups (twofold change; Figure 1b) ; aorta had the highest number of regulated genes in common with either PA (192) or MAPCAs (111). At a fourfold change in expression however, there were no regulated genes common to all three tissues (Figure 1c) . PA had 3 genes in common and aorta had 17 genes in common. Notably, MAPCAs had a higher number (33) of gene expression changes compared with either PA or aorta tissue, and the majority of genes are upregulated. Supplementary Table S1 online lists the genes expressed most highly in each tissue type and their comparative level in the other two tissues.
To investigate the potential relevance of the altered gene expression profiles of MAPCAs, we used gene ontology (GO) analysis to quantitate the representation of genes among three functional classifications: Molecular Function, Biological Process, and Cellular Components. Analysis using ExPlain 3.0 was employed to explore statistically overrepresented groups and identify significantly represented GO categories. In the MAPCAs vs. aorta and PA vs. aorta groups at a P value cutoff of <0.01, approximately 200 GO classes were enriched in the upregulated gene set. Notably, the enriched GO classes include Vasculature Development, Angiogenesis, and Cell Proliferation. However at this cutoff level, only 1 GO class (Developmental Process) was enriched in both downregulated gene sets. In the MAPCAs vs. PA group as shown in Figure 3 , a total of 22 GO classes were enriched in the upregulated gene set (138 genes), including Developmental Process, Extracellular Matrix, and Cell Differentiation, at the Venn diagrams depict the genes with overlapping expression among three vessel types at a twofold change level (b), and a fold-change level (c) in the study group (one-way ANOVA corrected P value ≤ 0.05). AO, aorta; MAPCA, major aorto-pulmonary collateral artery; PA, pulmonary artery. 
Overview of the Gene Expression Patterns
To further examine whether MAPCAs gene expression segregated from these three anatomically contiguous vessels, hierarchical clustering analysis was performed based on the expression values to compare these three vessel groups. The expression heat map (Figure 4) shows the hierarchical clustering gene tree resulting from this analysis: the five lanes on the left are from MAPCAs samples, five samples from PA are in the middle lanes, and the three lanes on the right are from aorta samples. Of note, the clustering dendrogram at the top of Figure 4 shows that the PA and aorta groups are more closely related, even though the specimens are from different patients. Expression changes observed in the MAPCAs group were highly distinct from the other two groups despite the fact that PA and MAPCAs specimens are paired samples from the same patients, further indicating that MAPCAs have many unique changes in gene expression. Overall, the vessel types segregated into two major expression pattern groups indicated by the colored vertical bars at the right of the heat map, designated a-d. Group 1 consists of two subsets: (a, red bar) MAPCAs and PA upregulated and aorta downregulated; and (d, yellow bar) MAPCAs and PA downregulated and aorta upregulated. Group 2 (blue bars), which we designated as the MAPCAsspecific gene pattern, consists of two subsets: (b) MAPCAs upregulated, PA and aorta downregulated and (c) MAPCAs downregulated but PA and aorta upregulated.
Functional Gene Pathway Analysis Identifies Key Canonical Pathways Altered in MAPCAs
We have conducted functional analysis of genes with over twofold altered expression in the three vessel sample groups using Ingenuity Pathway Analysis software as well as the BioBase biological database and have identified several distinct relationships. The major gene network functions identified in both the MAPCAs vs. PA and MAPCAs vs. aorta comparison groups were Cardiovascular system development and function, Organismal development, and Tissue development. Cancer, Cell death and survival, and Nervous system development and function were the major groups represented in the PA vs. aorta comparison group. The statistically significant canonical pathways in each of the three tissue types are shown in Supplementary Tables S2-S4 online. Interestingly, we observed no statistically significant canonical pathway in the group of genes with over fourfold altered expression.
Confirmation of MAPCAs-Regulated Genes by RT-PCR
To confirm the differential expression observed in microarray experiments, we performed QRT-PCR analysis of eight representative genes: five upregulated genes, i.e., four and a half LIM domain-5 (FHL5), calsequestrin-2 (CASQ2), WAP four-disulfide core domain-1 (WFDC1), synaptotagminlike-2 (SYTL2), and calcium binding protein-1 (CABP1), and three downregulated genes, i.e., gremlin-1 and -2 (GREM1, GREM2) and secreted frizzled-related protein-1 (sFRP1). The upregulation was confirmed in all five genes by real-time quantitative RT-PCR. Two of three downregulated genes show highly concordant quantitative measurements ( Figure 5 ). For the eight confirmed genes, these QRT-PCR results represent a 90% concordance with the microarray data (i.e., highest expression level of those genes with high signal intensity on the microarray).
DISCUSSION
This study was conducted to identify the differentially expressed genes among three contiguous vessel types in tetralogy of Fallot patients with pulmonary atresia (TOF/PA) in order to determine whether there are distinct genetic differences among these arteries. The major focus was on MAPCAs because they are vessels unique to TOF disease. Two general features were evident from transcriptome comparisons. First, the majority of gene expression ratios were higher (>70%) in the MAPCAs vs. PA group, suggesting a general upregulation in gene expression in MAPCAs. Second, a much greater number of regulated genes were present in the aorta group compared with either PA or MAPCAs, and the proportion of upregulated or downregulated genes was similar in both comparison groups. A large number of highly regulated genes, with the majority upregulated in MAPCAs, were noted in this study. The top GO functional classification showed an enrichment of genes involved in the BMP signal pathway including Grem1, Grem2, and Aldh1a2. IL13ra2 and Spint2 genes are associated with transforming growth factor regulation and the extracellular region. The marked downregulation of the BMP antagonist proteins Grem1 and 2 is suggestive of the loss of a normally negative regulation of BMP signaling by preventing their interaction with their cell surface receptors. However, gremlin has also been shown to be capable of pro-angiogenic activity through BMP-independent mechanisms (15) .
We found that MAPCAs express several genes at levels significantly greater than in either PA or aorta, demonstrating that MAPCAs may indeed be distinguished from up-and downstream contiguous vessels. The genes observed to be most highly regulated have been shown to play a role in vascular biology and disease. FHL5 is also known as ACT, Activator of CREM (cAMP response element modulator) in murine Testes, and is reportedly involved in the induction of vascular smooth muscle cell growth and intimal hyperplasia in human -storage/buffer protein known to be present in the sarcoplasmic reticulum of cardiac muscle cells. CASQ2 controls the influx and efflux of Ca 2+ from the sarcoplasmic reticulum in maintaining the intracellular and sarcoluminal Ca 2+ concentration (17) . We speculate that upregulation of CASQ2 in MAPCAs may promote their dilation.
In this report of our initial investigations of the transcriptional profile of MAPCAs and the vessels to which they commonly connect, we report distinct transcriptome differences, many of which we believe will be worthy of further investigation. However, we acknowledge that the study has a limitation in that other potentially relevant vessel types from patients with and without TOF were necessarily not available for comparison. It is our intention to continue to broaden this study as tissue and resources allow, so that a fuller understanding of collaterals from various systemic origins, as well as other, apparently normal vessels may be achieved. Further, the biological significance of the highly overexpressed nature of the specific MAPCAs genes we report here still remains to be explored. In most cases, matched tissue specimens from the same patient could not be obtained for analysis, as their availability is not predictable. Therefore the influence of interpatient variation on the data cannot yet be assessed. For the five matched pairs we analyzed by gene-specific PCR, the data were similar to those of unpaired samples. Although pairing of tissue samples potentially provides valuable additional insight and may reduce signal "noise, " it also necessarily induces a degree of bias compared with randomized sampling.
In summary, our study compared gene expression differences among these three contiguous vessel types in order to determine if there are genetic differences among these arteries. We determined that MAPCAs express several genes at levels significantly greater than in either PA or aorta, demonstrating that MAPCAs may indeed be distinguished from up-and downstream contiguous vessels. Furthermore, the GO analysis revealed a complex pattern of gene expression and signaling pathways involved in MAPCAs biology.
The results presented in this study demonstrate, for the first time, specific genetic differences in MAPCAs biology that may ultimately help to explain their aberrant growth response to flow. As the first report focusing on the genes expressed these unusual vessels, it is an important initial step to understanding the complex biology of MAPCAs. We believe that a characterization of MAPCAs at a tissue and cellular level may enable the identification of key factors in their unusual negative response to blood flow, a characteristic that is unpredictable and presents challenges to repairs utilizing them as autograft materials.
METHODS
Patient Characteristics
Pulmonary arteries, collaterals, and aortic tissue samples were collected from patients undergoing surgical repair operations for TOF/ PA, MAPCAs. Specimens removed during surgical operations were collected under a protocol approved by the Internal Review Board for Human Subjects of Stanford University Medical Center, transported from the operating suite to the laboratory in cold saline immersed in ice, and portions were immediately stored at −80 °C for later mRNA analysis. Our patients were children less than 2 y of age with tetralogy of Fallot requiring surgical reconstruction. A total of 21 patients (35 specimens) with TOF/PA, MAPCAs (mean age 229 d, range 24-547 days) undergoing primary corrective RVOT reconstruction for tetralogy of Fallot and unifocalization of pulmonary arteries and MAPCAs were studied by microarray and/or PCR validation. There were no significant differences in age, sex, and surgical procedure between PA, MAPCAs, and aorta groups. Where possible, paired PA and MAPCAs samples obtained from the same patient were used for microarray study to minimize possible individual-or disease-specific confounding factors. Aortic samples were generally not paired with PA in patients and rarely paired with MAPCAs; i.e., we used aortic tissue from different patients for microarray study.
Analysis of mRNA Expression Profiles Using Microarrays
Five paired PA and MAPCAs specimens and three individual aorta specimens were used to characterize vessel-specific transcriptomes (i.e., sets of expressed genes defined by genome-wide microarray analyses of total RNA). Total RNA was isolated with TRIzol reagent (Invitrogen) according to the manufacturer's protocols, followed by an additional RNA purification with an RNAeasy Mini Kit (Qiagen, Valencia, CA). The quality of RNA was assessed by UV absorption spectrophotometry (NanoDrop Technologies, ThermoFisher) and on-chip electrophoretic separation and quantitation (Bioanalyzer 2100, Agilent Technologies, Santa Clara, CA). Only samples having an A260/A280 ratio between 1.8 and 2.1 and a 28S/18S ratio within 1.5-2 were further processed at Stanford University Medical School Protein and Nucleic Acid Research core facility using standard protocols for cRNA labeling, hybridization, and detection procedures to probe Affymetrix GeneChip Human Genome U133 Plus 2 cDNA array slides (Affymetrix, Santa Clara, CA). The GeneSpring software suite (Agilent Technologies) was used for statistical analysis and normalization of microarray data. In brief, raw array data CEL files were uploaded to the GeneSpring GX version 11.0.2. Probelevel data were then compiled, normalized, and transformed using RMA. The following criteria were applied to filter the differentially expressed transcript list: a fold change of >1.5 and a Wilcoxon rank sum test where P < 0.05 with Benjamini-Hochberg estimation of false discovery rate. The resulting list of differentially expressed transcripts was uploaded into the BioBase ExPlain 3.0 data system (BIOBASE GmbH, Germany) and Ingenuity IPA (Ingenuity Systems, Redwood City, CA) as the starting points for gene ontogeny analysis and generation of biological networks. In both systems, a P value is calculated to estimate the probability that each biological function and/or disease assigned to the dataset of interest is not due to chance alone. Selected genes were visualized in a molecular network using information contained in IPA and show the connectivity of the individual proteins. Additionally, differentially expressed transcripts and genes are classified either by proprietary ontologies or by MESH terms according to the categories of canonical pathways, therapeutic target, biomarker, and molecular mechanism. The statistical significance of the association between the dataset and the categories is estimated from the ratio of the number of proteins from the dataset that map to the category divided by the total number of 
